Potential Linagliptin-Induced Renal Impairment

Eiji Kutoh

Abstract


It is known that linagliptin, a novel DPP-4 inhibitor, can be used in patients even with severe renal impairment. So far, there have been no reports describing the clinical presentations and features of a patient with linagliptin-induced renal toxicity. A 66-year-old Japanese man had developed nausea and elevations of creatinine and potassium levels at 4 weeks after switching from sitagliptin to linagliptin. No emesis or diarrhea was noted. These renal parameters had slowly recovered after switching-back to sitagliptin. This slow recovery process may be due to the very long half-life of this drug. Although no single case report can prove case or effect of drugs, it is still safe that physicians carefully monitor renal function upon administration of linagliptin, especially in those with certain degrees of chronic kidney disease.




J Med Cases. 2012;3(6):361-364
doi: https://doi.org/10.4021/jmc807w

Keywords


DPP-4 inhibitor; Linagliptin; Sitagliptin; Renal impairment

Full Text: HTML PDF
 

Browse  Journals  

 

Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics

 

World Journal of Oncology

Gastroenterology Research

Journal of Hematology

 

Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity

 

Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research

 

Journal of Neurology Research

International Journal of Clinical Pediatrics

 

 
       
 

Journal of Medical Cases, monthly, ISSN 1923-4155 (print), 1923-4163 (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.journalmc.org   editorial contact: editor@journalmc.org    elmer.editorial@hotmail.com
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.


Disclaimer: The views and opinions expressed in the published articles are those of the authors and do not necessarily reflect the views or opinions of the editors and Elmer Press Inc. This website is provided for medical research and informational purposes only and does not constitute any medical advice or professional services. The information provided in this journal should not be used for diagnosis and treatment, those seeking medical advice should always consult with a licensed physician.